{"id":54486,"date":"2023-03-03T18:05:00","date_gmt":"2023-03-03T17:05:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/elevance-health-public-policy-institutes-study-on-long-covid-published-in-jama-health-forum-study\/"},"modified":"2023-03-03T18:05:00","modified_gmt":"2023-03-03T17:05:00","slug":"elevance-health-public-policy-institutes-study-on-long-covid-published-in-jama-health-forum-study","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/elevance-health-public-policy-institutes-study-on-long-covid-published-in-jama-health-forum-study\/","title":{"rendered":"Elevance Health Public Policy Institute\u2019s study on Long COVID published in JAMA Health Forum Study"},"content":{"rendered":"
\n

\nStudy Found Long COVID Associated With Increased Risk for Adverse Cardiovascular, Pulmonary Conditions and Mortality<\/b>\n<\/p>\n

INDIANAPOLIS–(BUSINESS WIRE)–Individuals who experience long COVID are at increased risk for a wide range of adverse cardiovascular and pulmonary conditions and mortality, according to a new study published in JAMA Health Forum. The study<\/a>, led by researchers at the Elevance Health Public Policy Institute, found substantially higher mortality rates for individuals with long COVID than what had been found in previous studies.\n<\/p>\n

\nFor the study — the largest national study of commercially insured individuals with long COVID that includes 12 months of follow up — researchers examined utilization claims data for 13,435 US adults with long COVID and 26,870 US adults with no signs of COVID-19 for at least 18 months. After controlling for risk factors present pre-COVID-19, the researchers found that individuals diagnosed with long COVID, known in the medical literature as post-COVID-19 condition (PCC), were more likely to seek care for the following adverse outcomes:\n<\/p>\n